Clinical Trials Browser

Terminated × Docetaxel × 1 year × Clear all

NCT05062980 2026-06-03

Acclaim-2

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03199885 2026-05-29

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Terminated

190 enrolled 13 charts

Breast Neoplasms

NCT04154956 2026-05-18

CARMEN-LC03

Phase 3 Terminated

389 enrolled 16 charts

Non-small Cell Lung Cancer Metastatic

NCT00183937 2026-05-15

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

Phase 2 Terminated

15 enrolled 11 charts

Prostatic Neoplasms

NCT03337698 2026-05-12

Morpheus Lung

Phase 1/2 Terminated

314 enrolled 31 charts

Carcinoma, Non-Small-Cell Lung

NCT02257619 2026-04-21

Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT05567835 2026-04-09

TOGAR

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT02997332 2026-03-23

MEDINDUCTION

Phase 1 Terminated

Head and Neck Neoplasms

NCT06038539 2026-03-13

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Phase 3 Terminated

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

NCT05381909 2026-02-20

A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumor, Adult

NCT04037527 2026-02-04

Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities

Phase 1 Terminated

Sarcoma

NCT04095689 2026-01-23

INTEGRAL

Phase 2 Terminated

8 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Phase 2 Terminated

GynecologicSarcoma

Advanced Endometrial Cancer

NCT02688803 2025-12-04

OTT15-04

Phase 4 Terminated

2 enrolled 4 charts

Breast Neoplasms

NCT04854499 2025-11-19

ELEVATE HNSCC

Phase 2 Terminated

193 enrolled 27 charts

Squamous Cell Carcinoma of Head and Neck

NCT04396535 2025-11-17

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

10 enrolled 17 charts

Lung Neoplasms

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Phase 2 Terminated

4 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT01382706 2025-10-09

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Phase 2 Terminated

15 enrolled 10 charts

Urinary Bladder Neoplasms

NCT05733351 2025-09-15

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04921358 2025-06-29

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Terminated

377 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung